MedTrace Logo

A Study to Evaluate if AC-084 is Safe, Its Fate in the Body as Well as Its Potential Effects on the Body in Healthy Subjects

NCT02905253 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2018-07-10

No results posted yet for this study

Summary

The primary purpose of this first-in-man study is to investigate whether AC-084 is safe and well-tolerated when orally administered at single- and multiple-ascending dose to healthy adults

Conditions

  • Healthy Subjects

Interventions

DRUG

AC-084

Hard gelatin capsules for oral administration formulated in strengths of 1 mg, 10 mg, and 100 mg

DRUG

Placebo

Placebo capsules matching AC-084 capsules

Sponsors & Collaborators

  • Idorsia Pharmaceuticals Ltd.

    lead INDUSTRY

Principal Investigators

  • Martine Géhin, PhD · Actelion

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-09-12
Primary Completion
2017-12-10
Completion
2017-12-10

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02905253 on ClinicalTrials.gov